FDA's STAMP program
This article was originally published in The Gray Sheet
Executive Summary
Whole blood coagulation test systems will be the focus of a public workshop tentatively scheduled for Aug. 13 in Washington, D.C. as part of FDA's Systematic Technology Assessment of Medical Products program and co-sponsored by the College of American Pathologists. Medical experts, industry reps and regulators have been invited to develop a project proposal for standardization of whole blood coagulation devices. The proposal would be presented to the International Society on Thrombosis and Haemostasis scientific subcommittee on control of anticoagulation at its Aug. 14 meeting in Washington, D.C
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.